High Intensive Focused Ultrasound
---An Innovative Technology of Tumor Therapy

INDICATION SCOPE:
Primary and secondary hepatic carcinoma, pancreatic carcinoma, renal carcinoma, adrenocorticalo adenocarcinoma, ventriculi carcinoma, colon carcinoma, rectal carcinoma, endometrial carcinoma, cervical carcinoma, leiomyosarcoma of the uterus, breast carcinoma, ovary carcinoma, bladder carcinoma, prostate carcinoma, peritoneal carcinoma, osteosarcoma, parenchyma sarcoma, etc.
TECHNOLOGY THEORY:
1.Targeting by ultrasound.
2.The ultrasound focuses from concave, and generates high power(heat of 80-120℃),which causes coagulative necrosis of the targeted carcinoma cells . So the carcinoma cells are killed functionally.
3.Under computer auto-control, the carcinoma cells are killed one point after another, until the whole tumor is treated.
4.The necrotic carcinoma cells are discharged by alimentary canal or absorbed by the body. The damages are rehabilitated gradually.
ADVANTAGES OF THE TREATMENT:
 Painless, woundless, no anesthesia needed in treatment, real-time positioning and monitoring, 4-dimension treatment.
 Minimum complications and side effects, no perforation and skin burn.
 Improve the patient's immune system. Increase the curative effect of actinotheraphy and chemotherapeutics.
 No wastes and no radioactive contamination, no special protection needed.
 Over 9 years' clinical experience, proven safety and efficiency.
 Low cost, high efficiency.
THE THERAPY APPARATUS:
FEP-BP Serial High Intensive Focused Ultrasound Tumor Therapy System. The system has been granted many international and domestic patents. After rounds of reviews and appraisals by top professionals from both domestic and abroad, the clinical application of the technological is recognized to be in the leading position in the world.
CLINICAL EXPERIENCE:
Vacant viscera tumors:
Sorts of carcinoma Patient number Cure rate* Positive rate Disability rate
Rectal carcinoma 501 110(22.0%) 335(66.9%) 56(11.1%)
Bladder carcinoma 481 213(42.5%) 216(44.9%) 52(10.8%)
Colon carcinoma 212 84(39.6%) 104(49.1%) 24(11.3%)
Ventriculi carcinoma 76 41(54%) 26(34.2%) 9(11.8%)
Total 1270 448(35.3%) 681(53.6%) 141(11.1)

Solid viscera tumors:
Sorts of carcinoma Patient number Cure rate* Positive rate Disability rate
Hepatic carcinoma 919 105(11.4%) 676(73.6) 138(15%)
Matastatic carcinoma of peritoneal lymph node 462 66(14.3%) 353(76.4%) 43(9.3%)
Prostate carcinoma 234 63(26.9%) 163(69.7%) 8(3.4%)
Renal carcinoma 59 11(18.6%) 43(72.9%) 5(8.5%)
Adrenocorticalo adenocarcinoma 65 9(13.9%) 48(73.9%) 8(12.3%)
Breast carcinoma 234 104(44.4%) 105(44.9%) 25(10.7%)
Recrudescence of leiomyosarcoma 34 5(14.7%) 27(79.4%) 2(5.9%)
Recrudescence of ovary carcinoma 57 13(22.8%) 38(66.7%) 6(10.5%)
Cholecyst carcinoma 31 2(6.5%) 24(77.4%) 5(16.1%)
Recrudescence of cervix carcinoma 12 4(33.3%) 6(50%) 2(16.7%)
Mile's recrudescence in situ after rectal carcinoma surgery 102 42(41.2%) 50(49%) 10(9.8%)
Liposarcoma 40 8(20%) 30(75%) 2(5%)
Peritoneal lymphoma 57 13(22.8%) 38(66.7%) 6(10.5%)
Recrudescence of nerve fibre sarcoma 15 6(40%) 7(46.7%) 2(13.3%)
Rear peritoneal carcinoma 9 5(55.6%) 4(44.4%) 0
Osteosarcoma 3 2(66.7%) 1(33.3%) 0
Pancreatic carcinoma 768 160(20.8%) 524(68.2%) 84(10.9%)
Total 3088 615(19.9%) 2125(68.9%) 348(11.2%)

Some of the follow-up cases:
Sorts of carcinoma Patient number Survival rate after 1 year Survival rate after 2 years
Bladder carcinoma 71 95.8 87.3
Rectal carcinoma 89 85.4 78.7
Hepatic carcinoma 142 40.8 12
Pancreatic carcinoma 149 16.1 6.9
Prostate carcinoma 32 93.8 81.3
(Cure rate*: after the HIFU treatment, no cancer cells are found by existing examine means in 5 years )
TYPICAL CASES:
Here are some pictures showing the tissue changes before and after the HIFU treatment (in the accessory).
PUBLISHED PAPER:
1. Ultrasonographic Study of High Intensity Focused Ultrasound in Rabbit VX2 Renal Tumor. Hu Xiao-yi. Fudan University Journal of Medical Sciences. 2005,32(6):79-82
2. Investigation of rabbit VX2 renal tumor treated by high intensity focused ultrasound with following-up contrast CT. Hu Xiao-yi. Chin J Exp Sur, w2005,22(9): 483-485
3. Application of High Intensity Focused Ultrasound in Treating 45 cases of Carcinoma of Pancreas. Gu Yong-sheng. 2004,31(2):135-141
4. Therapeutic Effects of High Intensity Focused Ultrasound in the Treatment of Subcutaneous Prostae Carcinoma of Mice. Wu Rui-yi. Fudan University Journal of Medical Sciences. 2004,31(1):15-18
5. Application of High Intensity Focused Ultrasound in Treating Celiac and Pelvic Cavity Tumor. Wang Guo-min. 2004,10(11):26-29
6. An experimental study on high intensity focused ultrasound combined with mitomycin treatment of bladder tumor. Wang Guo-min. Chin J Surg, 2003, 41(12):897-900
7. Evaluation of the Effect of CDFI in the Abdominal and Pelvic Tumors Treatment by HIFU. Gu Yong-zhu. Fudan University Journal of Medical Sciences. 2003,30(2):139-142
8. The Acesodyne Effect of high Intensity Focused Ultrasoun on the Treatment of Advanced Pancreatic Carcinoma. Xu Ye-qing. Clinical Medical Journal of China. 2003,10(3):322-323
9. Effect of High Intensity Focused Ultrasound in Combination with Mitomycin on T Lymphocyte Level of T739 Mice. Yang Yuan-feng. 2002,29(6): 483-485

The Hospital Address: High Intensive Focused Ultrasound Therapy Center of 452 Hospital of PLA(No.18, Shunjiang Road, Chengdu, Sichuan Province, China,610000)
E-mail: hifu-452@hotmail.com
Tel: 0086-028-54522452